FDA Inspection 1319552 — Antonio Gil-Nagel, MD, PhD

Antonio Gil-Nagel, MD, PhD — FEI 3043304650

The FDA completed an inspection of Antonio Gil-Nagel, MD, PhD on May 8, 2026 in Madrid. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.

Inspection Details

Classification
No Action Indicated (NAI)
End Date
May 8, 2026
Fiscal Year
2026
Product Type
Drugs
Project Area
Bioresearch Monitoring
Location
Madrid (Spain)

Additional Details

Clinical Investigator (CI)

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.